ITEM 147-1010-R0510

Approval of University System/Employee Equity Interest and/or Business Participation Under MUSP 407; The University of Montana.

THAT

The Board of Regents of Higher Education approves UM-Missoula employees Dr. David Poulsen and Dr. Thomas Rau for ownership of an equity interest in and for work as a part-time employees of Sinapis Pharma, a Delaware corporation. The Board of Regents of Higher Education further authorizes The University of Montana-Missoula to enter into agreements and contractual arrangements with Sinapis Pharma, Inc. for use of University facilities and use of certain other resources.

EXPLANATION

Dr. David J. Poulsen, a Research Associate Professor and Dr. Thomas Rau, Post Doctoral Fellow, are both UM employees in the Department of Biomedical & Pharmaceutical Sciences. They seek approval to hold equity in and to serve as part-time employees of Sinapis Pharma, Inc., a Delaware corporation established to develop applications of neuroprotective agents for the treatment of stroke and traumatic brain injury in clinical settings.

Dr. Poulsen and Dr. Rau will work in accordance with conflict management plans developed by UM. Under Policy 407 and MCA 20-25-109, university employees must have board approval to serve as officers, employees, or to hold an equity interest in a business entity which has an agreement with, or shares ownership of intellectual property with, the university, relating to the development, licensing or commercial exploitation of that intellectual property.

UM benefits from this approval. By allowing this University-private sector relationship, intellectual property developed at The University of Montana can be used to set an example for other entrepreneurs from the University looking for opportunities for commercialization of their innovations and creations, and will generate goodwill for University employees and the private sector. The University will incur no net cost by entering into any arrangements covered by this agreement.

ATTACHMENTS

Submission Form